Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227 Meeting Abstract


Authors: Borghaei, H.; Hellmann, M. D.; Paz-Ares, L. G.; Ramalingam, S. S.; Reck, M.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F. E.; Brahmer, J. R.
Abstract Title: Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 460s
Language: English
ACCESSION: WOS:000442916003175
DOI: 10.1200/JCO.2018.36.15_suppl.9001
PROVIDER: wos
Notes: Meeting Abstract: 9001 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Matthew David Hellmann
    412 Hellmann